Guangzhou Innogen Pharmaceutical Group Co., Ltd., a China-based pharmaceutical company, has made an initial public offering (IPO) filing with the Hong Kong Stock Exchange. While the unit price and other key details of the offering have not been disclosed, the move marks a significant step in the company’s journey to expand its reach and secure funding for its innovative therapies.
Innogen Pharma’s Focus on Metabolic Diseases and Type 2 Diabetes
Founded in 2014, Innogen Pharma is dedicated to the development of innovative treatments for type 2 diabetes (T2D) and other metabolic diseases. The company’s lead program, efsubaglutide alfa, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, has been filed for marketing with the National Medical Products Administration, indicating progress towards commercialization.
Pipeline of Candidate Drugs
Innogen Pharma’s pipeline includes a range of candidate drugs at various stages of development. These include YN014 for Alzheimer’s disease (AD), YN202 for obesity and overweight conditions, YN209 for metabolic dysfunction associated with steatohepatitis (MASH), YN401 for type 1 diabetes (T1D), and YN203 for T2D. The pipeline’s breadth reflects the company’s commitment to addressing multiple aspects of metabolic health.
Financial Performance in 2024
For the first half of 2024, Innogen Pharma recorded R&D expenses of RMB 51.9 million (USD 7.1 million) and a loss of RMB 75.28 million (USD 10.4 million). These figures highlight the company’s investment in research and development as it works towards bringing new treatments to market.-Fineline Info & Tech
